CSL, Novartis flu-vaccines deal cleared by EU regulator
MLex Summary: The European Commission has unconditionally approved Australian drugmaker CSL’s plan to buy Swiss rival Novartis’s influenza vaccines business. The EU watchdog found that the proposed deal wouldn’t raise competition...To view the full article, register now.
Already a subscriber? Click here to view full article